PhD, MBA, MAICD
Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications. Ian is a co-inventor of the LEAP Technology.
Ian brings to Exopharm an extensive technical and entrepreneurial background in establishing, growing and operating technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development.
Before founding Exopharm, Ian co-founded Cynata Inc, a company that progressed the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX-CYP).
He is a non-executive director of Noxopharm Ltd (ASX-NOX), a founder of Nyrada Inc. and co-inventor of Nyrada drug NYX-330. Ian founded Genscreen Pty Ltd (2003-2018), was a director of Cell Therapies Pty Ltd, and currently serves as a part-time executive director of Medigard Ltd (ASX:MGZ).
Dr Chris Baldwin received his PhD in Chemical Engineering from the University of Cambridge, while matriculated at Trinity College. Chris joined Exopharm in November 2019, bringing a wide range of global commercial experience to the company.
Most recently, Chris was responsible for Haemonetics’ largest and most profitable business unit across Asia Pacific, with P&L responsibilities from Taiwan to Pakistan. Previously responsible for all sales and marketing in Southeast Asia, Chris provided strategy leadership across Asia Pacific, including China.
Chris’ strategic focus and approach to management comes from his time at McKinsey and Company, where he served banking, pharmaceutical and NGO clients.
Healthcare became the focus of Chris’ career at New York Blood Center, where he was Executive Director for 8 years and responsible for the blood supply across the greater New York metropolitan area. He founded and currently serves as Chairman of APAC Bioplasma Solutions Pte, a company that helps blood services and hospitals make productive use of their excess donations.
Dr Gregor Lichtfuss holds a PhD in Medicine / clinical immunology from Monash University, a Master of Science in International Health from Humboldt University Berlin and a Diploma in Biologie (Virology and Genetics) from Humboldt University Berlin. Gregor is a co-inventor of the LEAP Technology.
Gregor brings significant entrepreneurial experience in creating biotechnology startups and health solutions, in-depth experience and knowledge in molecular science and technology as well as an understanding of international health systems and early-stage drug development.
Gregor worked in early-stage research commercialisation at the Spinnovator, the startup creation hub managed by Ascenion GmbH, where he was instrumental in laying the business foundation for Cardior Pharmaceuticals GmbH, a biotechnology company developing novel treatments for heart failure. He has also worked as a consultant to Brandon Capital Partners in Melbourne.